MorphoSys AG (MOR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:MorphoSys AG (MOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5166
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product includes MOR208, MOR202, MOR103, MOR106, and MOR107. It drugs are used for the treatment of various types of cancers, psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, solid tumors, eye disease, and other inflammatory diseases. Morphosys offers human combinatorial antibody library (HuCAL), a recombinant antibody technology which allows generation of therapeutic and diagnostic antibodies. The company provides clinical trials for cancer and inflammatory disorders. It also conducts research and development activities with pharmaceutical and biotechnology companies. The company owns a regional licensing agreement to develop and commercialize products in China, Taiwan, Hong Kong, and Macao. Morphosys is headquartered in Munich, Germany.

MorphoSys AG (MOR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MorphoSys AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Lanthio Pharma Raises US$6 Million In Series A Financing 13
Partnerships 14
MorphoSys Enters into Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
Licensing Agreements 21
Novartis Pharma to Enter into Licensing Agreement with Galapagos and MorphoSys 21
I-Mab Biopharma Enters into Licensing Agreement with MorphoSys 23
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 25
MorphoSys Enters into Licensing Agreement with Merck Serono 27
MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 28
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 30
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 31
Equity Offering 32
MorphoSys Raises USD239 Million in Public Offering of Shares 32
MorphoSys Raises USD124.3 Million in Private Placement of Shares 34
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 35
Acquisition 37
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 37
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys 38
MorphoSys AG – Key Competitors 39
MorphoSys AG – Key Employees 40
MorphoSys AG – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Aug 02, 2018: MorphoSys re­ports se­cond quarter 2018 fin­an­cial res­ults 42
May 02, 2018: MorphoSy Reports First Quarter 2018 Results 44
Mar 13, 2018: MorphoSys Presents Results for Fiscal Year 2017 46
Nov 07, 2017: MorphoSys Announces Third Quarter 2017 Results 49
Aug 03, 2017: MorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017 51
May 03, 2017: MorphoSys Reports Solid First Quarter 2017 53
Corporate Communications 55
Jul 24, 2018: MorphoSys Appoints Jennifer Herron as President of MorphoSys US and Executive Vice President, Global Commercial 55
May 17, 2018: Annual General Meeting of MorphoSys Elects New Supervisory Board Members 56
Apr 10, 2018: MorphoSys Nominates New Candidates for Supervisory Board 57
Oct 30, 2017: Dr. Markus Enzelberger Appointed MorphoSys’s Chief Scientific Officer 58
Product News 59
06/15/2018: MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018 59
05/18/2017: MorphoSys to Present Clinical Data on MOR-202 at Upcoming ASCO Annual Meeting 2017 60
05/17/2018: MorphoSys Announces Presentation of Clinical Data on CD38 antibody MOR202 at Upcoming EHA 2018 Conference 61
Product Approvals 62
Aug 08, 2018: MorphoSys and I-Mab Biopharma announce China IND submission of TJ202/MOR202 62
Clinical Trials 63
May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers 63
Feb 21, 2017: MorphoSys’s Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107 64
Other Significant Developments 65
Sep 05, 2017: MorphoSys Presents Vision for Growth at its Capital Markets Day 65
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67

List of Tables
MorphoSys AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Lanthio Pharma Raises US$6 Million In Series A Financing 13
MorphoSys Enters into Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
Novartis Pharma to Enter into Licensing Agreement with Galapagos and MorphoSys 21
I-Mab Biopharma Enters into Licensing Agreement with MorphoSys 23
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 25
MorphoSys Enters into Licensing Agreement with Merck Serono 27
MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 28
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 30
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 31
MorphoSys Raises USD239 Million in Public Offering of Shares 32
MorphoSys Raises USD124.3 Million in Private Placement of Shares 34
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 35
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 37
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys 38
MorphoSys AG, Key Competitors 39
MorphoSys AG, Key Employees 40
MorphoSys AG, Subsidiaries 41

List of Figures
MorphoSys AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[MorphoSys AG (MOR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nissin Electric Co Ltd (6641):企業の財務・戦略的SWOT分析
    Nissin Electric Co Ltd (6641) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Natera Inc (NTRA):企業の製品パイプライン分析2018
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers products such as panorama prenatal testing, pre-implantation genetic testing, miscarriage testing, g …
  • Yihai International Holding Ltd (1579):企業の財務・戦略的SWOT分析
    Yihai International Holding Ltd (1579) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • University of Leeds:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Leeds (University of Leeds) is an educational university that offers academic programs. The university offers undergraduate, post graduate, research degrees, online and distance learning educational programs. It offers education programs in the areas of arts, biological science …
  • Ross Stores Inc:戦略・SWOT・企業財務分析
    Ross Stores Inc - Strategy, SWOT and Corporate Finance Report Summary Ross Stores Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Aoyama Trading Co., Ltd.
    Aoyama Trading Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Aoyama Trading Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Kodiak Sciences Inc (KOD):製薬・医療:M&Aディール及び事業提携情報
    Summary Kodiak Sciences Inc (Kodiak Sciences), formerly Oligasis LLC is a drug development company that discovers new medicines for the healthcare sector. The company provides retinal medicines for treatment of wet and dry forms of age-related macular degeneration. It utilizes proprietary Bioconjuga …
  • Clean TeQ Holdings Ltd (CLQ):企業の財務・戦略的SWOT分析
    Summary Clean TeQ Holdings Ltd (Clean TeQ) is a clean technology company that offers air pollution control solutions using biotechnology-based processes. The company provides water treatment products such as advanced separations, advanced oxidation, encapsulated bacteria, continuous ionic filtration …
  • International Dairy Queen, Inc.:企業の戦略的SWOT分析
    International Dairy Queen, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Accuray Inc (ARAY):製品パイプライン分析
    Summary Accuray Inc (Accuray) carries out the development, manufacture and sale of personalized treatment solutions for radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. The company’s major produc …
  • Jack in the Box Inc (JACK):企業の財務・戦略的SWOT分析
    Jack in the Box Inc (JACK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Abivax SA (ABVX)-製薬・医療分野:企業M&A・提携分析
    Summary Abivax SA (Abivax) is a biotechnology company that researches, develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases. The company’s pipeline products comprise ABX464, a small molecule against HIV; ABX311 for chikungunya; ABX544 to …
  • Ulta Salon, Cosmetics & Fragrance Inc:戦略・SWOT・企業財務分析
    Ulta Salon, Cosmetics & Fragrance Inc - Strategy, SWOT and Corporate Finance Report Summary Ulta Salon, Cosmetics & Fragrance Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Cedars-Sinai Medical Center-医療機器分野:企業M&A・提携分析
    Summary Cedars-Sinai Medical Center (Cedars-Sinai), formerly Kaspare Cohn Hospital is an academic and medical center that provides healthcare services for patients and medical professionals, and research and education services. The center offers treatments for various conditions such as abdominal pa …
  • Ishihara Sangyo Kaisha Ltd (4028):企業の財務・戦略的SWOT分析
    Ishihara Sangyo Kaisha Ltd (4028) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Terex Corp:企業の戦略・SWOT・財務分析
    Terex Corp - Strategy, SWOT and Corporate Finance Report Summary Terex Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • TVS Motor Co Ltd:戦略・SWOT・企業財務分析
    TVS Motor Co Ltd - Strategy, SWOT and Corporate Finance Report Summary TVS Motor Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Bilfinger Tebodin BV:企業の戦略的SWOT分析
    Bilfinger Tebodin BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Envases Del Plata S.A.:企業の戦略・SWOT・財務分析
    Envases Del Plata S.A. - Strategy, SWOT and Corporate Finance Report Summary Envases Del Plata S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Carnival Group International Holdings Ltd:企業のM&A・事業提携・投資動向
    Carnival Group International Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Carnival Group International Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detaile …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆